138 related articles for article (PubMed ID: 16317004)
1. Involvement of endoplasmic reticulum stress in hereditary tyrosinemia type I.
Bergeron A; Jorquera R; Orejuela D; Tanguay RM
J Biol Chem; 2006 Mar; 281(9):5329-34. PubMed ID: 16317004
[TBL] [Abstract][Full Text] [Related]
2. Kidneys of mice with hereditary tyrosinemia type I are extremely sensitive to cytotoxicity.
Jacobs SM; van Beurden DH; Klomp LW; Berger R; van den Berg IE
Pediatr Res; 2006 Mar; 59(3):365-70. PubMed ID: 16492973
[TBL] [Abstract][Full Text] [Related]
3. Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability.
Jorquera R; Tanguay RM
Hum Mol Genet; 2001 Aug; 10(17):1741-52. PubMed ID: 11532983
[TBL] [Abstract][Full Text] [Related]
4. [Hereditary tyrosinemia: an endoplasmic reticulum stress disorder?].
Bergeron A; Jorquera R; Tanguay RM
Med Sci (Paris); 2003 Oct; 19(10):976-80. PubMed ID: 14613010
[TBL] [Abstract][Full Text] [Related]
5. Molecular Pathogenesis of Liver Injury in Hereditary Tyrosinemia 1.
Tanguay RM; Angileri F; Vogel A
Adv Exp Med Biol; 2017; 959():49-64. PubMed ID: 28755183
[TBL] [Abstract][Full Text] [Related]
6. Fumarylacetoacetate Hydrolase Knock-out Rabbit Model for Hereditary Tyrosinemia Type 1.
Li L; Zhang Q; Yang H; Zou Q; Lai C; Jiang F; Zhao P; Luo Z; Yang J; Chen Q; Wang Y; Newsome PN; Frampton J; Maxwell PH; Li W; Chen S; Wang D; Siu TS; Tam S; Tse HF; Qin B; Bao X; Esteban MA; Lai L
J Biol Chem; 2017 Mar; 292(11):4755-4763. PubMed ID: 28053091
[TBL] [Abstract][Full Text] [Related]
7. Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah-/- knockout mice model.
Orejuela D; Jorquera R; Bergeron A; Finegold MJ; Tanguay RM
J Hepatol; 2008 Feb; 48(2):308-17. PubMed ID: 18093685
[TBL] [Abstract][Full Text] [Related]
8. Renal proximal tubular cells acquire resistance to cell death stimuli in mice with hereditary tyrosinemia type 1.
Luijerink MC; van Beurden EA; Malingré HE; Jacobs SM; Grompe M; Klomp LW; Berger R; van den Berg IE
Kidney Int; 2004 Sep; 66(3):990-1000. PubMed ID: 15327392
[TBL] [Abstract][Full Text] [Related]
9. Tissue-specific FAH deficiency alters sleep-wake patterns and results in chronic tyrosinemia in mice.
Yang S; Siepka SM; Cox KH; Kumar V; de Groot M; Chelliah Y; Chen J; Tu B; Takahashi JS
Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22229-22236. PubMed ID: 31611405
[TBL] [Abstract][Full Text] [Related]
10. Activation of nuclear factor E2-related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development.
Marhenke S; Lamlé J; Buitrago-Molina LE; Cañón JM; Geffers R; Finegold M; Sporn M; Yamamoto M; Manns MP; Grompe M; Vogel A
Hepatology; 2008 Aug; 48(2):487-96. PubMed ID: 18666252
[TBL] [Abstract][Full Text] [Related]
11. Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation.
Colemonts-Vroninks H; Neuckermans J; Marcelis L; Claes P; Branson S; Casimir G; Goyens P; Martens GA; Vanhaecke T; De Kock J
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33375092
[TBL] [Abstract][Full Text] [Related]
12. Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death.
Vogel A; van Den Berg IE; Al-Dhalimy M; Groopman J; Ou CN; Ryabinina O; Iordanov MS; Finegold M; Grompe M
Hepatology; 2004 Feb; 39(2):433-43. PubMed ID: 14767996
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of dichloroacetate treatment in a murine model of hereditary tyrosinemia type 1.
Langlois C; Jorquera R; Finegold M; Shroads AL; Stacpoole PW; Tanguay RM
Biochem Pharmacol; 2006 May; 71(11):1648-61. PubMed ID: 16581029
[TBL] [Abstract][Full Text] [Related]
14. Cyclin B-dependent kinase and caspase-1 activation precedes mitochondrial dysfunction in fumarylacetoacetate-induced apoptosis.
Jorquera R; Tanguay RM
FASEB J; 1999 Dec; 13(15):2284-98. PubMed ID: 10593876
[TBL] [Abstract][Full Text] [Related]
15. Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I.
Al-Dhalimy M; Overturf K; Finegold M; Grompe M
Mol Genet Metab; 2002 Jan; 75(1):38-45. PubMed ID: 11825062
[TBL] [Abstract][Full Text] [Related]
16. Hereditary Tyrosinemia Type 1 in Turkey.
Aktuglu-Zeybek AC; Kiykim E; Cansever MS
Adv Exp Med Biol; 2017; 959():157-172. PubMed ID: 28755194
[TBL] [Abstract][Full Text] [Related]
17. Rescue from neonatal death in the murine model of hereditary tyrosinemia by glutathione monoethylester and vitamin C treatment.
Langlois C; Jorquera R; Orejuela D; Bergeron A; Finegold MJ; Rhead WJ; Tanguay RM
Mol Genet Metab; 2008 Mar; 93(3):306-13. PubMed ID: 18023223
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Targeting of Fumaryl Acetoacetate Hydrolase in Hereditary Tyrosinemia Type I.
Gil-Martínez J; Macias I; Unione L; Bernardo-Seisdedos G; Lopitz-Otsoa F; Fernandez-Ramos D; Lain A; Sanz-Parra A; Mato JM; Millet O
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670179
[TBL] [Abstract][Full Text] [Related]
19. Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC).
Luijerink MC; Jacobs SM; van Beurden EA; Koornneef LP; Klomp LW; Berger R; van den Berg IE
J Hepatol; 2003 Dec; 39(6):901-9. PubMed ID: 14642604
[TBL] [Abstract][Full Text] [Related]
20. Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1.
Hickey RD; Mao SA; Glorioso J; Elgilani F; Amiot B; Chen H; Rinaldo P; Marler R; Jiang H; DeGrado TR; Suksanpaisan L; O'Connor MK; Freeman BL; Ibrahim SH; Peng KW; Harding CO; Ho CS; Grompe M; Ikeda Y; Lillegard JB; Russell SJ; Nyberg SL
Sci Transl Med; 2016 Jul; 8(349):349ra99. PubMed ID: 27464750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
